<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Exanthematous (maculopapular) drug eruption
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Exanthematous (maculopapular) drug eruption
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Exanthematous (maculopapular) drug eruption
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andreas J Bircher, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Axel Trautmann, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Maja Mockenhaupt, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 12, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H14870341">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exanthematous (maculopapular) drug eruption, also called morbilliform (measles-like) drug-induced exanthem, is the most common drug hypersensitivity reaction [
         <a href="#rid1">
          1,2
         </a>
         ]. It is characterized by a disseminated, and occasionally generalized, symmetric eruption of erythematous macules and/or papules  (
         <a class="graphic graphic_picture graphicRef54205 graphicRef86509" href="/z/d/graphic/54205.html" rel="external">
          picture 1A-B
         </a>
         ) that occur approximately one to two weeks after initiating treatment with the causative drug or, in previously sensitized individuals, as early as 6 to 12 hours and up to three days after initiating treatment with the causative drug. The exanthematous drug eruption should be differentiated from more severe forms of drug hypersensitivity, where the mucous membranes (oral, conjunctival, nasal, anogenital) and/or internal organs may be involved [
         <a href="#rid3">
          3,4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">
          "Drug reaction with eosinophilia and systemic symptoms (DRESS)"
         </a>
         .)
        </p>
        <p>
         This topic will focus on the clinical presentation, diagnosis, and treatment of exanthematous drug eruptions. Drug hypersensitivity in general, severe cutaneous drug reactions, cutaneous reactions to anticancer agents, and other types of cutaneous adverse drug reactions are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug hypersensitivity
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2086.html" rel="external">
          "Drug hypersensitivity: Classification and clinical features"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe cutaneous drug reactions
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">
          "Drug reaction with eosinophilia and systemic symptoms (DRESS)"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15761.html" rel="external">
          "Acute generalized exanthematous pustulosis (AGEP)"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cutaneous adverse reactions to anticancer therapies
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">
          "Cutaneous adverse effects of conventional chemotherapy agents"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">
          "Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/103060.html" rel="external">
          "Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2088.html" rel="external">
          "Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other types of cutaneous drug reactions
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15760.html" rel="external">
          "Fixed drug eruption"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">
          "Lichenoid drug eruption (drug-induced lichen planus)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1845178">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous drug reactions are estimated to occur in approximately 2 percent of individuals exposed to drugs [
         <a href="#rid1">
          1
         </a>
         ]. Reliable and reproducible data on the relative frequencies of different types of cutaneous drug reactions are lacking. It has been estimated that maculopapular exanthems account for 80 to 90 percent of cutaneous drug reactions, whereas reactions in the drug-induced anaphylaxis spectrum account for approximately 10 to 20 percent. Drug-specific reaction rates range from near 0 to greater than 5 percent among exposed patients, with the highest rates reported for antibiotics (eg, aminopenicillins, sulfonamides) and specific anticonvulsants (eg,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14870143">
         <span class="h1">
          PATHOGENESIS
         </span>
        </p>
        <p class="headingAnchor" id="H55253974">
         <span class="h2">
          Immunologic mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many, but not all, cases of drug-induced exanthem are thought to be delayed-type, T cell-mediated (type IV) immune reactions accompanied by the activation of several nonspecific effector cell types (eg, macrophages, eosinophils, or neutrophils) [
         <a href="#rid5">
          5
         </a>
         ]. The precise mechanism by which a low molecular weight drug (xenobiotic) elicits a specific immune response is not completely understood and may involve different types of interactions between drugs and immune receptors [
         <a href="#rid6">
          6
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/2072.html" rel="external">
          "Drug allergy: Pathogenesis", section on 'Interaction of drugs with the immune system'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs or their metabolites may act as haptens, form covalent bonds with an endogenous protein or peptide, and become antigenic. Haptenated proteins could then be processed by antigen-presenting cells (APCs) and bind to major histocompatibility complex (MHC) molecules. The hapten-peptide-MHC molecule complexes are then presented to T cells carrying an appropriate receptor, which together with costimulatory factors may activate and expand drug-reactive T cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs may directly interact with immune receptors and activate specific immune cells, proposed as the "p-i concept" (pharmacologic interactions of drugs with immune receptors). According to this concept, chemically inert drugs, unable to bind covalently to peptides or proteins, may activate T cells if they fit with sufficient affinity directly into T cell receptors or MHC molecules.
        </p>
        <p>
        </p>
        <p>
         In delayed-type immune reactions, activated T cells of the CD4 T helper type 1 (Th1) cell or T helper type 2 (Th2) cell and CD8 cytotoxic T cell subtypes may orchestrate different forms of inflammatory reactions, depending on the type of cytokines produced, leading to four subcategories of type IV reactions (IVa, IVb, IVc, and IVd)  (
         <a class="graphic graphic_figure graphicRef75626" href="/z/d/graphic/75626.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. Effector cells, such as CD4 Th1 lymphocytes, CD8 cytotoxic lymphocytes, macrophages, neutrophils, and eosinophils, may be involved in the elicitation phase, explaining to some extent the variability of the clinical reaction patterns of drug hypersensitivity [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         Exanthematous drug reactions appear to be predominantly caused by type IVc hypersensitivity  (
         <a class="graphic graphic_figure graphicRef75626" href="/z/d/graphic/75626.html" rel="external">
          figure 1
         </a>
         ), in which T cells act as effector cells. CD8 effector T cells migrate to the skin and cause tissue damage through perforin/granzyme B-mediated, granulysin-mediated, and FasL-mediated mechanisms [
         <a href="#rid10">
          10
         </a>
         ]. Immunohistochemical staining and functional experimental studies of drug-reactive T cells in patients with distinct forms of exanthems support the concept that distinct T cell subsets may lead to different clinical phenotypes [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         In clinical practice, the chronology of the onset and evolution of the skin lesions may provide clues about the type of pathomechanism involved  (
         <a class="graphic graphic_table graphicRef77196" href="/z/d/graphic/77196.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef86511" href="/z/d/graphic/86511.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H55254030">
         <span class="h2">
          Eliciting drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         A large number of drugs may induce delayed-type, T cell-mediated immune reactions, but only a limited number of them can be identified as unambiguous triggers in allergy testing (eg, aminopenicillins [
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         ], sulfamethoxazole,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         ). Some drugs act as haptens, bind to endogenous proteins, and then become full antigens. Examples include penicillins, cephalosporins, and agents with sulfhydryl groups. Possible antigenic determinants of beta-lactams include the aminobenzyl side chains, methoxyimino side chains, as well as core parts of the molecule [
         <a href="#rid11">
          11,12
         </a>
         ]. The exact antigenic determinant is not known for most drugs (eg, clindamycin, sulfonamides, anticonvulsants).
        </p>
        <p>
         For some drugs, biotransformation is necessary to form reactive metabolites. Examples include sulfonamides (sulfamethoxazole), anticonvulsants (eg,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ), and reverse transcriptase inhibitors (eg,
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          abacavir
         </a>
         ). For the latter, direct binding and transformation of the MHC has been shown [
         <a href="#rid13">
          13
         </a>
         ], although the exact mechanism is not fully established.
        </p>
        <p>
         Drugs that have been introduced within a timeframe of one to four weeks before the reaction or have been previously taken and are later reintroduced are more likely to be causative than drugs that have been taken for months or even years, especially when taken in an uninterrupted manner.
        </p>
        <p class="headingAnchor" id="H13763028">
         <span class="h1">
          GENETIC PREDISPOSITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic studies based upon the frequency of specific human leukocyte antigen (HLA) alleles suggest that there may be a genetic predisposition for drug hypersensitivity. Although there is strong evidence that certain HLA types confer an increased risk of severe cutaneous reactions (eg, Stevens-Johnson syndrome/toxic epidermal necrolysis [SJS/TEN], drug reaction with eosinophilia and systemic symptoms [DRESS]) to certain drugs, data on a possible association between exanthematous drug eruption and specific HLA alleles are still sparse and inconsistent [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy", section on 'Risk factors for drug allergy'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29586411">
         <span class="h1">
          CONTRIBUTING FACTORS
         </span>
        </p>
        <p class="headingAnchor" id="H13762867">
         <span class="h2">
          Underlying disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Concomitant diseases (eg, decreased liver or renal function) may predispose the patient to the development of an allergic drug reaction, presumably due to altered metabolic pathways, reduced excretion, or variations in the immunologic response to drugs. Viral infections, particularly Epstein-Barr virus, cytomegalovirus, and human herpesviruses 6 and 7, are associated with an increased risk of cutaneous drug eruptions [
         <a href="#rid16">
          16-18
         </a>
         ]. Patients with hereditary immunodeficiencies, acquired immunodeficiency (eg, HIV infection, iatrogenic immunosuppression, cystic fibrosis), and some autoimmune disorders are also prone to develop drug-induced exanthem [
         <a href="#rid3">
          3,16,19,20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13762874">
         <span class="h2">
          Comedication
         </span>
         <span class="headingEndMark">
          —
         </span>
         The concomitant intake of multiple medications may result in a more frequent occurrence of drug-induced exanthem, although the specific mechanism is still unclear [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15255950">
         <span class="h1">
          HISTOPATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In routine histology, exanthematous drug eruptions typically reveal a subtle, vacuolar interface dermatitis, with scattered, dyskeratotic keratinocytes along the dermoepidermal junction zone  (
         <a class="graphic graphic_picture graphicRef86550" href="/z/d/graphic/86550.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid22">
          22
         </a>
         ]. Usually, there is a superficial, perivascular, and interstitial infiltrate of lymphocytes, neutrophils, and eosinophils. Additional features may include pronounced extravasation of erythrocytes, accumulation of lymphocytes aligned along the dermoepidermal junction, and fibrin deposition within the blood vessel walls of the papillary vascular plexus.
        </p>
        <p>
         Although histopathologic patterns may support the clinical suspicion of a drug-induced exanthem, they cannot be reliably differentiated from those seen in a viral exanthem [
         <a href="#rid23">
          23
         </a>
         ]. Thus, a "histologically proven" diagnosis of drug-induced exanthem is not possible.
        </p>
        <p class="headingAnchor" id="H14870356">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H2524502876">
         <span class="h2">
          Latency
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients not previously sensitized, the onset of the cutaneous eruption typically occurs within 7 to 10 days (range 5 to 21 days) after starting treatment. Thus, for short courses of treatment (eg, antibiotics), the eruption may appear two to four days after stopping treatment. This relatively short latency time also suggests that a drug introduced one to three weeks before the reaction is much more likely to be responsible than a drug taken regularly for months or even years. In patients previously sensitized to the causative drug or a cross-reactive substance, the reaction may develop as early as 6 to 12 hours, or typically one to three days, after renewed treatment initiation.
        </p>
        <p class="headingAnchor" id="H1188559805">
         <span class="h2">
          General features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exanthematous drug eruption typically presents with erythematous macules and/or papules, described as "morbilliform" (measles like) or "rubelliform" (rubella like), that predominantly involve the trunk and proximal extremities  (
         <a class="graphic graphic_picture graphicRef86509 graphicRef86552 graphicRef70062 graphicRef54205" href="/z/d/graphic/86509.html" rel="external">
          picture 1A-D
         </a>
         ) [
         <a href="#rid8">
          8
         </a>
         ]. In mild forms, acral sites are often spared, whereas in more severe cases, the face, palms, and soles may also be involved. Purpuric lesions may develop on the legs and other dependent areas or under therapy with anticoagulants.
        </p>
        <p>
         Systemic symptoms are generally mild and may include pruritus and low-grade fever; slightly elevated, acute-phase proteins; and mild eosinophilia.
        </p>
        <p class="headingAnchor" id="H1366656">
         <span class="h2">
          Intertriginous and flexural reaction pattern
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE; formerly called "baboon syndrome") is an uncommon form of drug eruption, most often induced by antibiotics  (
         <a class="graphic graphic_picture graphicRef86506" href="/z/d/graphic/86506.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid24">
          24,25
         </a>
         ]. In rare instances, SDRIFE may be the manifestation of systemically elicited allergic dermatitis due to the systemic exposure to nickel or mercury. However, only limited data support this concept [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         SDRIFE occurs a few hours to a few days after the administration of the offending drug  (
         <a class="graphic graphic_figure graphicRef86511" href="/z/d/graphic/86511.html" rel="external">
          figure 2
         </a>
         ). The eruption presents as a sharply demarcated, V-shaped erythema in the gluteal/perianal or inguinal/perigenital area, often with involvement of at least one other flexural skin region, such as the axillae, antecubital fossae, or popliteal fossae of the knee  (
         <a class="graphic graphic_picture graphicRef86506" href="/z/d/graphic/86506.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid8">
          8,24,28
         </a>
         ].
        </p>
        <p>
         SDRIFE should be differentiated from the so-called "malignant intertrigo," an intertriginous form of acral erythema (also called hand-foot syndrome) caused by conventional chemotherapy agents [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/142102.html" rel="external">
          "Toxic erythema of chemotherapy (hand-foot syndrome)", section on 'Hand-foot syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H45737162">
         <span class="h1">
          CLINICAL COURSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most exanthematous drug eruptions are of mild to moderate severity and do not cause major morbidity. Typically, the eruption evolves rapidly, reaching the maximal extent approximately two to four days after discontinuation of the causative drug, and resolves in one to three weeks  (
         <a class="graphic graphic_figure graphicRef86511" href="/z/d/graphic/86511.html" rel="external">
          figure 2
         </a>
         ). A mild eruption may subside within a few (three to seven) days.
        </p>
        <p>
         Resolution often occurs with some desquamation. In patients with darkly pigmented skin, postinflammatory hyperpigmentation may occur. (See
         <a class="medical medical_review" href="/z/d/html/95847.html" rel="external">
          "Postinflammatory hyperpigmentation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H55253960">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H1881280930">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of exanthematous drug eruption is primarily clinical, based on clinical and medication history, timing of initial drug administration and onset of symptoms, and physical examination  (
         <a class="graphic graphic_algorithm graphicRef139962" href="/z/d/graphic/139962.html" rel="external">
          algorithm 1
         </a>
         ). Concurrent infections, comorbidities, and immunosuppression should be ascertained. Establishing a temporal association between drug administration and onset of the eruption remains a key element for the identification of the causative drug.
        </p>
        <p>
         There is no specific or reliable laboratory test to diagnose a drug eruption (see
         <a class="local">
          'Allergy testing'
         </a>
         below). Routine laboratory tests (eg, blood count with differential, liver and kidney function tests) should be checked at least once, even if the clinical picture does not indicate a systemic reaction. However, whereas a mild elevation of liver transaminases is still compatible with the diagnosis of an (uncomplicated) maculopapular eruption, a more than twofold increase of liver transaminases or a decreased kidney function may indicate a more severe, systemic hypersensitivity reaction (ie, drug reaction with eosinophilia and systemic symptoms [DRESS]). A skin biopsy is not routinely performed, but it may be warranted if the diagnosis is uncertain or there is suspicion for a severe (bullous) drug reaction. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         It should be noted that in the absence of specific diagnostic tests, exanthematous drug eruptions are often misdiagnosed, especially in childhood and adolescence, as they cannot be differentiated with sufficient reliability from viral or some other exanthems neither clinically nor histopathologically [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14324195">
         <span class="h2">
          Identification of the causative drug
         </span>
         <span class="headingEndMark">
          —
         </span>
         Establishing a chronologic association between first drug administration and onset of the cutaneous eruption provides an important clue to the identification of the causative drug. (See
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy", section on 'Identification of the suspect drug'
         </a>
         .)
        </p>
        <p>
         Key elements to be considered include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Current and past medication history
         </strong>
         – The patient should be questioned about current and past (within the last four weeks) medications, including over-the-counter drugs, supplements, natural and herbal remedies, and topical preparations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Simultaneous exposure to multiple drugs
         </strong>
         – Identifying a particular drug as the cause of an exanthematous eruption is especially difficult when the patient is taking multiple drugs. In such a situation, it may be helpful to know the relative frequency of cutaneous reactions for specific drugs [
         <a href="#rid1">
          1,2,30-32
         </a>
         ]. Drugs that most commonly elicit exanthematous eruption are aminopenicillins (
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         ),
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          allopurinol
         </a>
         , other beta-lactam antibiotics (
         <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">
          piperacillin
         </a>
         , cephalosporins), non-beta-lactam antibiotics (sulfonamides,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         , tetracyclines), anticonvulsants (
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ), antiretroviral drugs (
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          abacavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         ), and radio contrast media.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Previously sensitized patients
         </strong>
         – A short latency time (6 to 12 hours and up to a few days) between first administration of the potential, causative drug and onset of the eruption suggests that sensitization may have taken place with a past exposure to the same drug or to a cross-reacting drug component.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Accidental re-exposure
         </strong>
         – In patients with a previous history of a drug reaction, accidental re-exposure may occur due to the use of a drug marketed under different brand names or use of over-the-counter products or "natural remedies" containing the offending agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Resolution of the rash after drug withdrawal
         </strong>
         – Resolution of the maculopapular eruption after withdrawal of the suspected drug supports the diagnosis of drug etiology. However, it cannot be considered as proof of causality. Resolution is usually completed within one to two weeks after the causative drug is discontinued. In some cases with a prolonged course, resolution may take up to three weeks.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3765782530">
         <span class="h2">
          When to suspect a severe drug reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         A severe cutaneous drug reaction, such as DRESS or Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), may appear at the very beginning as a maculopapular exanthem [
         <a href="#rid3">
          3,33,34
         </a>
         ]. A severe reaction should be suspected if systemic symptoms are present (eg, fever &gt;38°C/100.4°F, lymphadenopathy) and if blisters, erythroderma, erythematous facial swelling, or mucosal involvement develop  (
         <a class="graphic graphic_table graphicRef86557" href="/z/d/graphic/86557.html" rel="external">
          table 2
         </a>
         ). Laboratory testing and a skin biopsy are recommended for the diagnosis. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">
          "Drug reaction with eosinophilia and systemic symptoms (DRESS)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14324138">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         In case of suspected, drug-induced exanthem, liver and kidney function tests should be performed at least once, even if the clinical picture does not indicate a systemic reaction:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Liver and kidney function tests
         </strong>
         – A more than twofold increase of liver transaminases and/or abnormal kidney function tests may indicate a systemic, inflammatory reaction and prompt surveillance for the development of DRESS or other severe drug reactions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complete blood cell count with differential
         </strong>
         – Blood eosinophilia may support the diagnosis of a drug reaction, although it cannot reliably differentiate a drug-induced exanthem from an infectious exanthem. It is important to note, however, that a pronounced eosinophilia can be the heralding sign of DRESS. (See
         <a class="medical medical_review" href="/z/d/html/5691.html" rel="external">
          "Approach to the patient with unexplained eosinophilia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/120281.html" rel="external">
          "Infectious causes of peripheral eosinophilia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H198168590">
         <span class="h2">
          Skin biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A skin biopsy is not routinely necessary for the diagnosis of exanthematous drug eruption. The histopathologic findings (vacuolar interface dermatitis and tissue eosinophilia  (
         <a class="graphic graphic_picture graphicRef86550" href="/z/d/graphic/86550.html" rel="external">
          picture 2
         </a>
         )) may support the diagnosis but are nonspecific [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p>
         However, a skin biopsy may be warranted if the diagnosis is uncertain or there is concern for a more severe hypersensitivity reaction. (See
         <a class="local">
          'When to suspect a severe drug reaction'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3582458464">
         <span class="h2">
          Allergy testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical diagnosis of drug hypersensitivity based solely on the temporal relationship between drug intake and the development of an exanthem leads to a huge overestimation of the frequency of drug allergy [
         <a href="#rid35">
          35-37
         </a>
         ]. Therefore, allergy testing, if available, is recommended for all patients with suspected, drug-induced exanthem to rule out or confirm drug hypersensitivity, ideally within a time frame of one to six months after complete resolution of the rash. If allergy testing is not performed, many patients will be unnecessarily labeled (lifelong) as being drug allergic:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin testing
         </strong>
         – Methods include patch and intradermal testing; test fields should be
         <strong>
          evaluated for delayed reactions at days 2, 3, and 4
         </strong>
         . (See
         <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">
          "Patch testing"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy", section on 'Testing for delayed reactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In vitro testing
         </strong>
         – In specialized laboratories, blood samples may be examined with cell-based methods, such as lymphocyte transformation/activation testing, assays for upregulation of activation markers on T cells, cytokine production, and drug-induced cytotoxicity assay. However, the diagnostic sensitivity and specificity of these tests are variable, depending on the drug type and laboratory. Therefore, they should be considered investigational.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Provocation (challenge) testing
         </strong>
         – The sensitivity and specificity of skin testing are limited and primarily determined by the investigated drug/drug class. Therefore, especially in cases with negative skin test results, the suspicion of allergic drug hypersensitivity should be finally confirmed or excluded by drug challenge testing. (See
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy", section on 'Graded challenge and drug provocation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14870363">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of exanthematous drug eruption includes viral and bacterial exanthems, secondary syphilis, and rashes associated with systemic or cutaneous diseases  (
         <a class="graphic graphic_table graphicRef86513" href="/z/d/graphic/86513.html" rel="external">
          table 3
         </a>
         ). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adds to the long list of viruses causing a maculopapular rash, which may closely mimic a drug-induced exanthem [
         <a href="#rid38">
          38,39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/127978.html" rel="external">
          "COVID-19: Cutaneous manifestations and issues related to dermatologic care"
         </a>
         .)
        </p>
        <p>
         The morphology, distribution, and spatial and temporal evolution of the rash and results of laboratory testing (eg, serologic tests, bacterial cultures) may be helpful in distinguishing a drug-induced exanthem from a viral or bacterial exanthem or a rash associated with a systemic or cutaneous disease  (
         <a class="graphic graphic_table graphicRef86513" href="/z/d/graphic/86513.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid9">
          9,40,41
         </a>
         ].
        </p>
        <p>
         It is also important to differentiate an exanthematous drug eruption from the prodromal phase of a severe cutaneous drug reaction, such as acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)  (
         <a class="graphic graphic_table graphicRef86557" href="/z/d/graphic/86557.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid33">
          33,34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15761.html" rel="external">
          "Acute generalized exanthematous pustulosis (AGEP)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">
          "Drug reaction with eosinophilia and systemic symptoms (DRESS)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14870405">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H45737196">
         <span class="h2">
          Drug withdrawal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prompt withdrawal of the offending drug is the mainstay of treatment for maculopapular drug eruption. However, in patients taking multiple drugs, every effort should be made to stop only the most suspicious drug(s) and not several or all drugs. Moreover, if the drug is urgently needed and no suitable alternative is available, drug treatment may also remain unchanged under close medical supervision [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="local">
          ''Treating through''
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H45737203">
         <span class="h2">
          Symptomatic treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of exanthematous drug eruptions is supportive. For symptomatic relief of skin lesions and pruritus, we suggest a topical corticosteroid and an oral antihistamine. We generally use a high-potency topical corticosteroid  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 4
         </a>
         ) one to two times per day for one week or until resolution. We prefer second-generation, nonsedating agents (eg,
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         or
         <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">
          loratadine
         </a>
         ).
        </p>
        <p>
         Systemic corticosteroids are generally unnecessary. However, in patients with a more severe or widespread exanthem accompanied by intense pruritus, a short course of a moderate-dose systemic corticosteroid (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         0.5 to 1 mg/kg per day for three to five days) may be beneficial [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         The efficacy of antihistamines and anti-inflammatory drugs for the treatment of exanthematous drug eruptions has not been evaluated in randomized trials, and their use is mainly based on clinical experience.
        </p>
        <p class="headingAnchor" id="H1367407">
         <span class="h2">
          'Treating through'
         </span>
         <span class="headingEndMark">
          —
         </span>
         "Treating through" means the continuation of a drug treatment in the setting of a
         <strong>
          mild
         </strong>
         , cutaneous hypersensitivity reaction. This strategy may be considered in particular clinical scenarios, specifically when the condition being treated is serious and an effective alternative treatment is lacking [
         <a href="#rid44">
          44
         </a>
         ]. In such cases, the benefit of the continuation of an effective therapy has to be carefully weighed against the risk of worsening the exanthem or the progression of the exanthem. Comedication with a corticosteroid or an antihistamine may reduce the risk of the progression of the exanthem but has not been well studied.
        </p>
        <p>
         There is limited evidence in support of "treating through" from case series of patients with HIV/AIDS who were treated with co-trimoxazole for prophylaxis or treatment of opportunistic infections [
         <a href="#rid45">
          45
         </a>
         ]. In a series of 18 patients with severe, bacterial soft tissue infections who experienced a drug-induced, maculopapular eruption, urgently indicated antibiotic therapy was maintained under strict medical supervision. The eruption improved in 12 patients despite the continuation of treatment, while 6 patients required replacement with an alternative agent [
         <a href="#rid42">
          42
         </a>
         ]. An algorithm to support the difficult and complicated decision leading to "treating through" has been published [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H198168284">
         <span class="h2">
          Patient education
         </span>
         <span class="headingEndMark">
          —
         </span>
         During the acute phase of the drug reaction, patients should be educated about warning signs of more severe drug hypersensitivity reactions. These include high fever, facial swelling (edema), mucosal symptoms, skin tenderness, development of pustules or blisters, and jaundice  (
         <a class="graphic graphic_table graphicRef86557" href="/z/d/graphic/86557.html" rel="external">
          table 2
         </a>
         ). Patients should seek immediate medical attention if any of these signs develop. (See
         <a class="local">
          'When to suspect a severe drug reaction'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H14870241">
         <span class="h1">
          PREVENTION
         </span>
        </p>
        <p class="headingAnchor" id="H1367579">
         <span class="h2">
          Avoidance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should be counseled to avoid the offending drug and possibly cross-reacting drugs in the future. They should be provided with a list (eg, in an allergy card or document [
         <a href="#rid46">
          46
         </a>
         ]) including the generic and a selection of brand names of the causative drug as well as possibly cross-reacting drugs. (See
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy", section on 'Long-term management of patients prone to drug allergy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1367499">
         <span class="h2">
          Premedication
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do
         <strong>
          not
         </strong>
         suggest premedication with a corticosteroid and/or an antihistamine for the prevention of an exanthematous drug eruption in a sensitized patient. The efficacy of this premedication regimen for preventing a delayed-type allergic drug hypersensitivity reaction in sensitized patients has not been evaluated in case series nor in randomized trials.
        </p>
        <p class="headingAnchor" id="H14870248">
         <span class="h2">
          Desensitization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Desensitization to induce temporary drug tolerance is an established practice in the management of immediate-type hypersensitivity reactions [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p>
         There is little evidence for the efficacy and safety of desensitization in T cell-mediated, delayed-type drug hypersensitivity reactions [
         <a href="#rid48">
          48
         </a>
         ]. However, in patients with a history of mild to moderate exanthem who are in repeated need of a drug (eg,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         in HIV infection or antibiotics in cystic fibrosis), desensitization may be an option [
         <a href="#rid19">
          19,45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy", section on 'Desensitization to the culprit drug'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H399188347">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109237.html" rel="external">
          "Society guideline links: Drug allergy and hypersensitivity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1367506">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology and pathogenesis
         </strong>
         – Exanthematous (maculopapular) drug eruption is by far the most common clinical manifestation of drug hypersensitivity, occurring in approximately 2 percent of individuals exposed to drugs. Most exanthematous drug eruptions are thought to represent delayed-type, T cell-mediated allergic hypersensitivity  (
         <a class="graphic graphic_table graphicRef77196" href="/z/d/graphic/77196.html" rel="external">
          table 1
         </a>
         ). Although these reactions may occur with a large variety of drugs, only a limited number of drugs can be regularly identified as unambiguous triggers by allergy testing (eg, aminopenicillins [
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         ], sulfamethoxazole,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         ). Genetic predisposition, concomitant viral infection (eg, Epstein-Barr virus, human herpesvirus), and the administration of multiple drugs may all increase the risk of an exanthematous drug eruption. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Genetic predisposition'
         </a>
         above and
         <a class="local">
          'Contributing factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Exanthematous drug eruptions are characterized by erythematous macules and/or papules that predominantly involve the trunk and proximal extremities  (
         <a class="graphic graphic_picture graphicRef86509 graphicRef54205 graphicRef70062 graphicRef86552" href="/z/d/graphic/86509.html" rel="external">
          picture 1A-D
         </a>
         ). Mucosal involvement is usually absent. In the case of sensitization during ongoing treatment, the rash usually develops within one to two weeks after the beginning of drug administration, but in previously sensitized patients, it may occur as early as 6 to 12 hours and up to one to three days after starting treatment. Systemic symptoms are generally mild and may include pruritus, low fever, and mild eosinophilia. After withdrawal of the offending drug, resolution is to be expected within one to two weeks  (
         <a class="graphic graphic_figure graphicRef86511" href="/z/d/graphic/86511.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="local">
          'Clinical presentation'
         </a>
         above and
         <a class="local">
          'Clinical course'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of an exanthematous drug eruption is suspected in patients with a characteristic rash that occurs in temporal relationship with the administration of a new drug  (
         <a class="graphic graphic_table graphicRef86515" href="/z/d/graphic/86515.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_picture graphicRef86509 graphicRef54205 graphicRef70062 graphicRef86552" href="/z/d/graphic/86509.html" rel="external">
          picture 1A-D
         </a>
         ). Resolution of the rash after drug discontinuation may support the diagnosis but by no means can be considered as proof. For all patients with a suspected exanthematous drug eruption, thorough drug allergy testing, if available, is recommended for confirming or ruling out drug hypersensitivity. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of an exanthematous drug eruption includes viral and bacterial exanthems, secondary syphilis, and rashes associated with systemic or dermatologic diseases  (
         <a class="graphic graphic_table graphicRef86513" href="/z/d/graphic/86513.html" rel="external">
          table 3
         </a>
         ). An exanthematous drug eruption may rarely be the heralding sign of a severe cutaneous drug hypersensitivity reaction. Warning signs include evolution to erythroderma, high fever, erythematous facial swelling, mucosal erosions, skin tenderness, and blistering  (
         <a class="graphic graphic_table graphicRef86557" href="/z/d/graphic/86557.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above and
         <a class="local">
          'When to suspect a severe drug reaction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Drug withdrawal
         </strong>
         – Prompt withdrawal of the offending drug is the mainstay of treatment for exanthematous drug eruptions. (See
         <a class="local">
          'Drug withdrawal'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Relieving symptoms
         </strong>
         – For symptomatic relief of exanthem and pruritus, we suggest a topical corticosteroid and an oral nonsedating antihistamine, such as
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         or
         <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">
          loratadine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We generally use a high-potency topical corticosteroid  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 4
         </a>
         ) one to two times per day for one week. Antihistamines are given orally until pruritus subsides. We suggest
         <strong>
          not
         </strong>
         routinely using systemic corticosteroids for the treatment of uncomplicated exanthematous drug eruptions (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, in patients with very intense cutaneous symptoms, a course of a moderate-dose systemic corticosteroid for three to five days may be beneficial. (See
         <a class="local">
          'Symptomatic treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          "Treating through"
         </strong>
         – "Treating through" means the continuation of a drug treatment in the setting of a
         <strong>
          mild
         </strong>
         , cutaneous hypersensitivity reaction. In select patients who develop an exanthem during treatment of a severe (oftentimes infectious) disease, the benefit of continuing an effective drug (oftentimes an antibiotic) under close medical supervision by a specialist in drug allergy has to be weighed against the risk of worsening the cutaneous eruption or progression of the cutaneous eruption. Given the very limited evidence from small case series, this approach should be pursued with great caution. (See
         <a class="local">
          ''Treating through''
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – Patients should be counseled to avoid the offending drug and cross-reacting substances in the future. They should be provided with an allergy card or document containing a list of the generic and brand names of the causative drug. (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256:3358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy 2014; 69:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Böhm R, Proksch E, Schwarz T, Cascorbi I. Drug Hypersensitivity. Dtsch Arztebl Int 2018; 115:501.
          </a>
         </li>
         <li class="breakAll">
          Pichler WJ. Drug hypersensitivity reactions: Classification and relationship to T-cell activation. In: Drug Hypersensitivity, Pichler WJ (Ed), Karger Publishers, 2007. p.168.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam J, Pichler WJ, Yerly D. Delayed drug hypersensitivity: models of T-cell stimulation. Br J Clin Pharmacol 2011; 71:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lerch M, Pichler WJ. The immunological and clinical spectrum of delayed drug-induced exanthems. Curr Opin Allergy Clin Immunol 2004; 4:411.
          </a>
         </li>
         <li class="breakAll">
          Bircher AJ. Uncomplicated drug-induced disseminated exanthemas. In: Chemical Immunology, French L (Ed), Karger Publishers, 2012.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedmann PS, Pickard C, Ardern-Jones M, Bircher AJ. Drug-induced exanthemata: a source of clinical and intellectual confusion. Eur J Dermatol 2010; 20:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pichler WJ, Adam J, Daubner B, et al. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin North Am 2010; 94:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ariza A, Mayorga C, Fernandez TD, et al. Hypersensitivity reactions to β-lactams: relevance of hapten-protein conjugates. J Investig Allergol Clin Immunol 2015; 25:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Gaeta F, Arribas Poves MF, Valluzzi RL. Cross-Reactivity among Beta-Lactams. Curr Allergy Asthma Rep 2016; 16:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redwood AJ, Pavlos RK, White KD, Phillips EJ. HLAs: Key regulators of T-cell-mediated drug hypersensitivity. HLA 2018; 91:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sukasem C, Chaichan C, Nakkrut T, et al. Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients. J Immunol Res 2018; 2018:2780272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shafeng N, Han DF, Ma YF, et al. Association between the HLA-B*1502 gene and mild maculopapular exanthema induced by antiepileptic drugs in Northwest China. BMC Neurol 2021; 21:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stokes SC, Tankersley MS. HIV: practical implications for the practicing allergist-immunologist. Ann Allergy Asthma Immunol 2011; 107:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tohyama M, Hashimoto K. New aspects of drug-induced hypersensitivity syndrome. J Dermatol 2011; 38:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aota N, Shiohara T. Viral connection between drug rashes and autoimmune diseases: how autoimmune responses are generated after resolution of drug rashes. Autoimmun Rev 2009; 8:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitaker P, Shaw N, Gooi J, et al. Rapid desensitization for non-immediate reactions in patients with cystic fibrosis. J Cyst Fibros 2011; 10:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spoerl D, Scherer K, Tyndall A. Aspects of allergy in rheumatology. Clin Exp Rheumatol 2011; 29:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaub N, Bircher AJ. Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. Allergy 2000; 55:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Justiniano H, Berlingeri-Ramos AC, Sánchez JL. Pattern analysis of drug-induced skin diseases. Am J Dermatopathol 2008; 30:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seitz CS, Rose C, Kerstan A, Trautmann A. Drug-induced exanthems: correlation of allergy testing with histologic diagnosis. J Am Acad Dermatol 2013; 69:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 2004; 51:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuler AM, Smith EH, Chaudet KM, et al. Symmetric drug-related intertriginous and flexural exanthema: Clinicopathologic study of 19 cases and review of literature. J Cutan Pathol 2021; 48:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lerch M, Bircher AJ. Systemically induced allergic exanthem from mercury. Contact Dermatitis 2004; 50:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan MG, Pratt MD, Burns BF, Glassman SJ. Baboon syndrome from mercury showing leukocytoclastic vasculitis on biopsy. Contact Dermatitis 2020; 83:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan SC, Tan JW. Symmetrical drug-related intertriginous and flexural exanthema. Curr Opin Allergy Clin Immunol 2011; 11:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith SM, Milam PB, Fabbro SK, et al. Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition. JAAD Case Rep 2016; 2:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 1998; 51:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulthanan K, Chularojanamontri L, Manapajon A, et al. Cutaneous adverse reactions to fluoroquinolones. Dermatitis 2011; 22:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, et al. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. J Clin Psychiatry 2009; 70:1258.
          </a>
         </li>
         <li class="breakAll">
          Scherer K, Bircher AJ. Danger signs in drug hypersensitivity. In: Drug Hypersensitivity, Pichler WJ (Ed), WB Saunders, 2010. p.681.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bircher AJ. Symptoms and danger signs in acute drug hypersensitivity. Toxicology 2005; 209:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benahmed S, Picot MC, Dumas F, Demoly P. Accuracy of a pharmacovigilance algorithm in diagnosing drug hypersensitivity reactions. Arch Intern Med 2005; 165:1500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wöhrl S, Vigl K, Stingl G. Patients with drug reactions -- is it worth testing? Allergy 2006; 61:928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seitz CS, Bröcker EB, Trautmann A. Diagnosis of drug hypersensitivity in children and adolescents: discrepancy between physician-based assessment and results of testing. Pediatr Allergy Immunol 2011; 22:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shams S, Rathore SS, Anvekar P, et al. Maculopapular skin eruptions associated with Covid-19: A systematic review. Dermatol Ther 2021; 34:e14788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mirza FN, Malik AA, Omer SB, Sethi A. Dermatologic manifestations of COVID-19: a comprehensive systematic review. Int J Dermatol 2021; 60:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drago F, Rampini E, Rebora A. Atypical exanthems: morphology and laboratory investigations may lead to an aetiological diagnosis in about 70% of cases. Br J Dermatol 2002; 147:255.
          </a>
         </li>
         <li class="breakAll">
          Bircher AJ. Approach to the patient with a drug hypersensitivity reaction - clinical perspectives. In: Drug Hypersensitivity, Pichler WJ (Ed), Karger Publishers, 2007. p.352.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trautmann A, Benoit S, Goebeler M, Stoevesandt J. "Treating Through" Decision and Follow-up in Antibiotic Therapy-Associated Exanthemas. J Allergy Clin Immunol Pract 2017; 5:1650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trubiano JA, Soria A, Torres MJ, Trautmann A. Treating Through Drug-Associated Exanthems in Drug Allergy Management: Current Evidence and Clinical Aspects. J Allergy Clin Immunol Pract 2021; 9:2984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin D, Li WK, Rieder MJ. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst Rev 2007; :CD005646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brockow K, Aberer W, Atanaskovic-Markovic M, et al. Drug allergy passport and other documentation for patients with drug hypersensitivity - An ENDA/EAACI Drug Allergy Interest Group Position Paper. Allergy 2016; 71:1533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010; 65:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scherer K, Brockow K, Aberer W, et al. Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68:844.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15762 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2946876" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11405768" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Rates of cutaneous reactions to drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24697291" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : International Consensus on drug allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30135011" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Drug Hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30135011" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Drug Hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21480949" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Delayed drug hypersensitivity: models of T-cell stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15349041" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The immunological and clinical spectrum of delayed drug-induced exanthems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15349041" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The immunological and clinical spectrum of delayed drug-induced exanthems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20123640" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Drug-induced exanthemata: a source of clinical and intellectual confusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20609855" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Drug hypersensitivity reactions: pathomechanism and clinical symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25898690" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Hypersensitivity reactions toβ-lactams: relevance of hapten-protein conjugates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26898316" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cross-Reactivity among Beta-Lactams.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29171940" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : HLAs: Key regulators of T-cell-mediated drug hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29546073" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34488672" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Association between the HLA-B*1502 gene and mild maculopapular exanthema induced by antiepileptic drugs in Northwest China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21704878" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : HIV: practical implications for the practicing allergist-immunologist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21342223" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : New aspects of drug-induced hypersensitivity syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19239928" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Viral connection between drug rashes and autoimmune diseases: how autoimmune responses are generated after resolution of drug rashes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21388896" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Rapid desensitization for non-immediate reactions in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21418783" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Aspects of allergy in rheumatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10726736" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18645307" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pattern analysis of drug-induced skin diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23932649" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Drug-induced exanthems: correlation of allergy testing with histologic diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15606657" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34159622" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Symmetric drug-related intertriginous and flexural exanthema: Clinicopathologic study of 19 cases and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15274725" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Systemically induced allergic exanthem from mercury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32462678" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Baboon syndrome from mercury showing leukocytoclastic vasculitis on biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21659857" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Symmetrical drug-related intertriginous and flexural exanthema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27981223" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9743319" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Skin reactions to antibacterial agents in general practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21569745" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Cutaneous adverse reactions to fluoroquinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19538904" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19538904" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15767037" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Symptoms and danger signs in acute drug hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16009865" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Accuracy of a pharmacovigilance algorithm in diagnosing drug hypersensitivity reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16867044" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Patients with drug reactions -- is it worth testing?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21309856" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Diagnosis of drug hypersensitivity in children and adolescents: discrepancy between physician-based assessment and results of testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33481314" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Maculopapular skin eruptions associated with Covid-19: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33141443" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Dermatologic manifestations of COVID-19: a comprehensive systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12174095" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Atypical exanthems: morphology and laboratory investigations may lead to an aetiological diagnosis in about 70% of cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12174095" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Atypical exanthems: morphology and laboratory investigations may lead to an aetiological diagnosis in about 70% of cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28499779" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : "Treating Through" Decision and Follow-up in Antibiotic Therapy-Associated Exanthemas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17919775" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33878455" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Treating Through Drug-Associated Exanthems in Drug Allergy Management: Current Evidence and Clinical Aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17443608" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27145347" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Drug allergy passport and other documentation for patients with drug hypersensitivity - An ENDA/EAACI Drug Allergy Interest Group Position Paper.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20716314" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : General considerations on rapid desensitization for drug hypersensitivity - a consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23745779" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
